Novo Nordisk to Invest $113M in Insulin Production Site Expansion

Apr 22, 2016

Denmark-based Novo Nordisk announced plans to invest $113 million in production facilities at its existing 345,000 square feet site in Chartres, France.

The expansions will help Novo meet the increasing global demand for diabetes medicines. The Chartres site produces a range of the company's insulin products, including FlexPen, the world's leading insulin injection device.

The French site expansion will also grow the workforce by 20 percent. The site current employs 1,100 employees.

Read the Novo press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments